A Phase II, Multicenter, Open-label Single Arm Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs BL 8040 (Primary) ; Pembrolizumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms COMBAT
- Sponsors BioLineRx
- 21 Nov 2017 According to a BioLineRx media release, partial results from the monotherapy portion from this trial will be presented at the ASCO GI conference and abstract for this presentation will be published prior to the conference in January 2018.
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2017 Top line results from this trial are expected in H2 2018 according to a BioLineRx media release.